<DOC>
	<DOCNO>NCT00669864</DOCNO>
	<brief_summary>This trial conduct Asia . This single arm trial aim evaluate blood glucose control twice daily biphasic insulin aspart 30 combination metformin Chinese subject type 2 diabetes inadequately control twice daily basal insulin .</brief_summary>
	<brief_title>Effect Biphasic Insulin Aspart 30 Combined With Metformin Blood Glucose Control Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Currently treat basal insulin twice daily without oral antidiabetic drug ( OADs ) least 3 month HbA1c ( glycosylated haemoglobin A1c ) within range 7.5 % to10.0 % ( inclusive ) BMI ( Body Mass Index ) maximum 40 kg/m2 Metformin contraindication accord local practice Systemically treat TZDs ( thiazolidinediones ) one month within 6 month prior trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>